Global ribonucleic acid (RNA) markers market is estimated to be valued at US$ 226.6 million in 2023 and is expected to exhibit a CAGR of 8.76% during the forecast period (2023-2030). Increasing investment for research and development activities by the government is expected to assist in the growth of the market over the forecast period. For instance, in the year 2020, Sanofi, a pharmaceutical company and GSK, a pharmaceutical and Biotechnology Company, entered into a collaboration agreement with the U.S. government, in order to increase the development and manufacturing of a COVID-19 recombinant protein-based vaccine. Under this agreement, the U.S. government provided US$ 2.1 billion, which was used for the development of vaccine, clinical trials, scale up and distribution of approximately 100 million doses of vaccines.
Analysts’ Views on Global Ribonucleic Acid (RNA) Markers Market:
The ribonucleic acid (RNA) markers market's growth is expected to increase over the forecast period. This is due to the increasing demand of RNA vaccines, especially during the COVID-19 pandemic as many manufacturers started conducting more research and development activities for the production of COVID-19 mRNA vaccines. Moreover, the demand of RNA markers will also increase in future for the development of new medicines and vaccines.
Figure 1.Global Ribonucleic Acid (RNA) Markers Market Share (%), by Type, 2023
Global Ribonucleic Acid (RNA) Markers Market- Driver
Facility expansion by the market players to drive the growth of the Ribonucleic Acid (RNA) Markers Market
Market players are indulged in facility expansion, which is expected to increase the production of nucleic acid products including RNA markers, which is expected to drive the growth of the Ribonucleic Acid (RNA) markers market over the forecast period. For instance, in November 2022, Celerion, a clinical research organization (CRO), expanded its molecular and cellular capabilities to Good Laboratory Practice/Good Clinical Practice (GLP/GCP) standards, in order to support the development of new modality therapies, such as cell and gene therapies. The expanded service offering is available in both of the company’s locations, i.e., Lincoln and Zürich bioanalytical laboratories and this includes ELISpot analysis, flow cytometry, and qPCR
Figure 2. Global Ribonucleic Acid (RNA) Markers Market Share (%), by Region, 2022
Global Ribonucleic Acid (RNA) Markers Market- Regional Analysis
Among all regions, North America region is expected to dominate the market over the forecast period. This is attributed due to the North America hold 34.6% market share owing to increasing research and development activities by the market players in the North America region. For instance, in the year 2021, Pfizer Inc., a pharmaceutical and Biotechnology company invested a total of US$ 120 million in four clinical-stage biotech companies, as part of the Pfizer Breakthrough Growth Initiative (PBGI), during the second half of the year 2020. Through PBGI, Pfizer Inc., invested up to US$ 500 million in biotechnology companies, which will provide funding and further access to Pfizer’s scientific expertise, which in turn, will help in the completion of the clinical development programs. Such investments are expected to increase the use of RNA markers and help in the growth of the market over the forecast period.
Europe region is expected to be the second largest region over the forecast period. Due to increasing investment for research and development activities by the market players. For instance, in June 2022, GSK plc, announced an investment of approximately US$ 1.08 million over ten years, in order to accelerate research and development (R&D) activities for infectious diseases that disproportionately impact lower-income countries. This is expected to increase the use of RNA markers for research and development activities. This research will increase production of disruptive vaccines and medicines, for the prevention and treatment of malaria, tuberculosis, HIV, neglected tropical diseases (NTDs), and anti-microbial resistance (AMR).
Global Ribonucleic Acid (RNA) Markers Market– Impact of Coronavirus (COVID-19) Pandemic
During the COVID-19 pandemic there was increase in the growth of the global ribonucleic acid (RNA) markers market owning to launch of RNA extraction kits during COVID-19 pandemic. In the year 2021, Porvair Sciences, engaged in the development and manufacture of raw materials, launched new kits for rapid extraction of total RNA from a wide range of biological samples. These proprietary kits enable extraction of up to 1000 µg (microgram) of application-ready pure RNA in as little as 10 minutes. Extraction of RNA is the first step to identify any viral contamination and all the research after the extraction of RNA from the samples.
Moreover, due to increasing research and development activities for the production of COVID-19 vaccines, market players were collaborating by supplying raw materials required for the production of vaccines, which also included RNA markers. For instance, in 2020, Sanofi and BioNTech entered into an agreement under which Sanofi supported the manufacturing and supply of BioNTech’s COVID-19 mRNA vaccine, which was being co-developed with Pfizer Inc. Under this agreement, Sanofi provided BioNTech the access to its established infrastructure and expertise to produce over 125 million doses of COVID-19 mRNA vaccine in Europe.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 226.6 Mn |
| Historical Data for: | 2017 to 2021 | Forecast Period: | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR: | 8.76% | 2030 Value Projection: | US$ 407.9 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Agilent Technologies, Inc., Oxford Gene Technology IP Limited, PerkinElmer Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, NextGen Life Sciences Private Limited, bioMérieux SA, New England Biolabs, Promega Corporation, Merck KGaA, Takara Bio Inc., Abnova Corporation, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories, Inc., Lonza, CardioNet, ZOLL Medical Corporation and Hill-Rom Services, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Ribonucleic Acid (RNA) Markers Market Segmentation:
The global ribonucleic acid (RNA) markers market report is segmented into Type, Application, and End User
Based on Type, the market is segmented into Prestained markers, Unstained Markers and Specialty markers. Out of which, prestained markers is expected to dominate the ribonucleic acid (RNA) markers market during the forecast period and this is attributed due to high demand of prestained markers for the research and development activities.
Based on Application, the market is segmented into Nucleic acid applications and Proteomics Applications. Out of which, nucleic acid applications segment is expected to dominate the market over the forecast period
Based on End User, the ribonucleic acid (RNA) markers market is segmented into research centers, pharmaceutical and biotechnology companies and others. Research centers segment is expected to dominate the market over the forecast period and this is attributed to the higher research and development activities carried out by the market players.
Among all segmentation, by type segment has highest potential due to high demand of ribonucleic acid (RNA) markers products. Therefore, most of the manufacturers such as Funakoshi Co., Ltd., Jena Bioscience GmbH, Diagnocine and others are manufacturing RNA markers.
Global Ribonucleic Acid (RNA) Markers Market Cross Sectional Analysis:
In End User segment, research centers held dominant position in the North America region due to increasing research and development funding by the government authorities for conducting research and development activities. For instance, according to the article published in the year 2021, “U.S. Investments in Medical and Health Research and Development”, the U.S. medical and health research and development reached US$ 245.1 billion in the year 2020, out of which, the U.S. state governments spent US$ 2.1 billion on health research and development (0.9%)
Global Ribonucleic Acid (RNA) Markers Market: Key Developments
On July 5, 2022, Eurofins Discovery, a U.S based drug discovery company, acquired contract research organization, DiscoveryBioMed, a life sciences and biotechnology company. This acquisition contributed to Eurofins Discovery's aim of offering array of drug discovery services and products.
Global Ribonucleic Acid (RNA) Markers Market: Restraint
Stringent Guidelines to handle RNA Sample
Stringent laboratory guidelines to handle RNA samples is expected to hamper the growth of the global ribonucleic acid (RNA) markers market, over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI): 2021, the following are some of the stringent guidelines mentioned, which if not followed may lead to the degradation of the RNA molecules:
Global Ribonucleic Acid (RNA) Markers Market: Key Players
Major players operating in the global ribonucleic acid (RNA) markers market include Agilent Technologies, Inc., Oxford Gene Technology IP Limited, PerkinElmer Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, NextGen Life Sciences Private Limited, bioMérieux SA, New England Biolabs, Promega Corporation, Merck KGaA, Takara Bio Inc., Abnova Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Lonza, CardioNet, ZOLL Medical Corporation and Hill-Rom Services, Inc.
Definition: RNA size markers contain a mixture of RNA fragments of known length, making them suitable for estimating the fragment length of concurrently run samples. Markers and ladders stain well with ethidium bromide and other common nucleic acid stains for visualization after gel electrophoresis.
A molecular marker (identified as genetic marker) is a fragment of DNA or RNA, which is associated with a certain location within the genome or RNA Pool. Molecular markers are used in molecular biology and biotechnology to identify a particular sequence of DNA or RNA in a pool of unknown nucleic acid sequence. RNA markers are used for the size estimation of single stranded RNA. For example, Promega Corporation, manufacturer of enzymes and other products for biotechnology and molecular biology is offering RNA markers and these markers are suitable for size estimation of single-stranded RNA from 0.28–6.58kb in glyoxal or formaldehyde-agarose gels. The RNA markers consist of a ladder of nine RNA transcripts that are synthesized in vitro from specific templates. The sizes are 281, 623, 955, 1,383, 1,908, 2,604, 3,638, 4,981 and 6,583 bases. The markers can be visualized by ethidium bromide staining.
Market Dynamics
Market players are indulged in expansion of manufacturing facilities, which is expected to drive the growth of the global ribonucleic acid (RNA) markers market, over the forecast period. For instance, on 20 January 2023, Moderna, Inc., an U.S. based pharmaceutical and biotechnology company, is planning to expand its manufacturing capacity in Canada, as part of a 10-year partnership with the Canadian government in order to strengthen the company’s pandemic response. Moreover, the company is also planning to expand its manufacturing facility in Australia, for the same reason as above. The company is also planning to expand its manufacturing facility in Kenya. The Australian facility is expected to produce up to 100 million mRNA vaccine doses annually, including for respiratory infections. The new facility in Kenya is expected to produce at least of 500 million vaccine doses per year.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients